



# AKPHAN

## ALASKA PUBLIC HEALTH ALERT NETWORK

---

*The following message was sent to you through the Alaska Public Health Alert Network (AK PHAN). Please share this information with others who may be interested. Note: Contact information for the Alaska Section of Epidemiology can be found at the end of this message.*

---

### Updated Recommendations for the Use of Respiratory Syncytial Virus Vaccine in Pregnancy and Nirsevimab for Infants during the 2025–26 Season

February 27, 2026

#### Background

- RSVpreF Vaccine
  - A single lifetime dose of Abrysvo maternal RSV vaccine is recommended during weeks 32 through 36 of pregnancy, seasonally administered from September through January 31, to reduce the chance of severe RSV in infants.
  - A previous PHAN expanded this interval through February 28, 2026.
- Nirsevimab
  - Nirsevimab is a monoclonal antibody that offers passive immunity against RSV in infants, protecting them from severe RSV-related illness.
  - Routine administration of nirsevimab is recommended for infants during their first RSV season and for select high-risk children during their second RSV season, from October 1 through March 31.
  - Note that [Alaska 2025-26 guidance](#) expanded this window though the month of April.
- [Jurisdictions like Alaska with unique RSV circulation patterns may adopt locally tailored recommendations](#) for RSVpreF and nirsevimab.
- RSV activity remains high in Alaska, as noted in the [AK Respiratory Virus Snapshot](#).

#### Updated Recommendation for RSVpreF Vaccine for this Season

- Due to ongoing RSV circulation in Alaska, SOE recommends that clinicians continue to offer:
  - RSVpreF vaccination during 32–36 weeks of pregnancy **through March 31, 2026**.
  - Nirsevimab administration for eligible infants **through May 31, 2026**.
- If RSV continues to circulate at elevated levels, further extensions may be considered.
- A second dose of **Beyfortus** is recommended for infants and children aged 8 through 19 months who remain at increased risk for severe RSV disease and meet the following criteria:
  - Are between 8 and 19 months of age at the time of administration; **and**
  - Have at least 6 months between the first and second doses.
- At this time, there are insufficient data to support administration of a third dose for high-risk children. Therefore, a third dose is not currently recommended.

## Resources

- Alaska PHAN (Feb 2, 2026): [Updated Recommendations for the Use of Respiratory Syncytial Virus Vaccine in Pregnancy and Nirsevimab for Infants during the 2025–26 Season](#)
- Alaska SOE RSV Immunization Guidance for 2025-26: [https://epi.alaska.gov/bulletins/docs/b2025\\_17.pdf](https://epi.alaska.gov/bulletins/docs/b2025_17.pdf)
- Alaska Respiratory Virus Snapshot: <https://health.alaska.gov/en/resources/respiratory-virus-snapshot>
- Alaska SOE RSV Webpage: <https://health.alaska.gov/dph/Epi/id/Pages/dod/rsv/default.aspx>
- CDC: [Clinical Guidance for RSV Immunizations and Vaccines](#)
- CDC: [RSV Immunization Guidance for Infants and Young Children.](#)